AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 200 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $503,000 | -69.1% | 9,400 | -72.4% | 0.05% | -81.1% |
| Q4 2019 | $1,628,000 | +10.7% | 34,100 | -24.9% | 0.24% | -4.3% |
| Q3 2019 | $1,471,000 | -63.1% | 45,400 | -43.2% | 0.25% | -46.8% |
| Q2 2019 | $3,990,000 | -1.4% | 80,000 | +33.3% | 0.48% | -2.1% |
| Q1 2019 | $4,046,000 | -6.7% | 60,000 | +6.7% | 0.49% | +5.9% |
| Q3 2018 | $4,335,000 | +58.6% | 56,207 | +17.6% | 0.46% | +34.9% |
| Q4 2017 | $2,733,000 | -14.4% | 47,799 | 0.0% | 0.34% | -17.0% |
| Q3 2017 | $3,191,000 | -49.8% | 47,799 | -61.3% | 0.41% | -40.9% |
| Q2 2017 | $6,359,000 | +112.7% | 123,599 | +141.4% | 0.70% | +99.1% |
| Q1 2017 | $2,990,000 | +30.5% | 51,200 | -6.7% | 0.35% | +37.4% |
| Q4 2016 | $2,291,000 | -17.7% | 54,900 | +4.2% | 0.25% | -7.0% |
| Q3 2016 | $2,784,000 | +84.1% | 52,700 | +46.0% | 0.27% | +75.0% |
| Q2 2016 | $1,512,000 | – | 36,100 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |